PMID- 36574919
OWN - NLM
STAT- MEDLINE
DCOM- 20230307
LR  - 20230307
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 171
DP  - 2023 Mar
TI  - Intraoperative Ventricular Opening has No Effect on Complication Development 
      Following BCNU Wafer Implantation for Malignant Glioma.
PG  - e707-e713
LID - S1878-8750(22)01796-X [pii]
LID - 10.1016/j.wneu.2022.12.090 [doi]
AB  - OBJECTIVE: To evaluate the safety profile of bis-chloroethyl-nitrosourea (BCNU) 
      wafer implantation after malignant glioma resection with or without ventricular 
      opening (VO). METHODS: This single-center retrospective study included 66 
      consecutive patients with BCNU wafer implantation after malignant glioma 
      resection between March 2013 and August 2021. The patients were categorized into 
      2 groups based on whether VO occurred during the malignant glioma resection. 
      Fifty-eight patients had glioblastoma, and 8 had anaplastic astrocytoma or 
      oligodendroglioma. Forty-eight patients underwent an initial treatment, and 18 
      underwent recurrent surgeries. Infection, hydrocephalus, subcutaneous fluid 
      collection, chronic subdural hematoma, early seizure after surgery within 
      1 month, symptomatic edema surrounding the resected cavity, cyst formation, and 
      postoperative hemorrhage were defined as adverse events (AEs). RESULTS: 
      Thirty-three patients underwent resection with VO, and 33 without. The median 
      survival time was 28 months in the initial treatment group and 11.5 months in the 
      recurrent treatment group. The with and without VO groups had similar median 
      survival times. Postoperative AEs occurred in 7/33 patients (21.2%) with VO and 
      10/33 (30.3%) without VO, with no difference between them (P = 0.574). 
      CONCLUSIONS: This study showed that VO during surgery with BCNU wafer 
      implantation might not influence the occurrence of postoperative AEs. If VO 
      happens, BCNU wafer implantation can be performed safely with accurate closing of 
      the ventricle.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Matsuda, Ryosuke
AU  - Matsuda R
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan. 
      Electronic address: rmatsuda@naramed-u.ac.jp.
FAU - Maeoka, Ryosuke
AU  - Maeoka R
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Tokuda, Noriaki
AU  - Tokuda N
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Nakazawa, Tsutomu
AU  - Nakazawa T
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Morimoto, Takayuki
AU  - Morimoto T
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan; 
      Department of Neurosurgery, Okanami General Hospital, Iga, Mie, Japan.
FAU - Kotsugi, Masashi
AU  - Kotsugi M
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Takeshima, Yasuhiro
AU  - Takeshima Y
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Tamura, Kentaro
AU  - Tamura K
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Yamada, Shuichi
AU  - Yamada S
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Nishimura, Fumihiko
AU  - Nishimura F
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Nakagawa, Ichiro
AU  - Nakagawa I
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Park, Young-Soo
AU  - Park YS
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
FAU - Nakase, Hiroyuki
AU  - Nakase H
AD  - Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221224
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
RN  - U68WG3173Y (Carmustine)
RN  - 0 (Antineoplastic Agents, Alkylating)
SB  - IM
MH  - Humans
MH  - Carmustine/adverse effects
MH  - *Brain Neoplasms/surgery
MH  - Retrospective Studies
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - *Glioma/surgery
MH  - Combined Modality Therapy
OTO - NOTNLM
OT  - Bis-chloroethyl-nitrosourea (BCNU) wafer
OT  - Gliadel
OT  - Glioblastoma;
OT  - Malignant glioma
OT  - Ventricular opening
EDAT- 2022/12/28 06:00
MHDA- 2023/03/08 06:00
CRDT- 2022/12/27 19:13
PHST- 2022/10/21 00:00 [received]
PHST- 2022/12/19 00:00 [revised]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2022/12/28 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
PHST- 2022/12/27 19:13 [entrez]
AID - S1878-8750(22)01796-X [pii]
AID - 10.1016/j.wneu.2022.12.090 [doi]
PST - ppublish
SO  - World Neurosurg. 2023 Mar;171:e707-e713. doi: 10.1016/j.wneu.2022.12.090. Epub 
      2022 Dec 24.